(Q35051019)

6 August 2017

1 reference

title

Liposomally targeted cytotoxic drugs for the treatment of cancer (English)

1 reference

6 August 2017

Kevin J Harrington

1

1 reference

PubMed ID

12542887

6 August 2017

Konstantinos N Syrigos

series ordinal

2

1 reference

PubMed ID

12542887

6 August 2017

Richard G Vile

series ordinal

3

1 reference

6 August 2017

1 December 2002

1 reference

Journal of Pharmacy and Pharmacology

6 August 2017

1 reference

6 August 2017

54

1 reference

6 August 2017

12

1 reference

6 August 2017

1573-1600

1 reference

Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity

6 August 2017

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

The carrier potential of liposomes in biology and medicine (second of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Caelyx: phase II studies in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase III data on Caelyx in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomes as carriers of antitumor agents: toward a clinical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Skin ulcers due to adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Doxorubicin in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Large unilamellar liposomes with low uptake into the reticuloendothelial system

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetics of stealth versus conventional liposomes: effect of dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Diffusion of univalent ions across the lamellae of swollen phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I study of liposomal daunorubicin in patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I study of liposomal vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

The carrier potential of liposomes in biology and medicine (first of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Drug-carrier potential of liposomes in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal doxorubicin in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Failure (and danger) of mitozantrone in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal distribution in malignant glioma: possibilities for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Antitumor effect of IL-2 liposome

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Lack of vesicant injury following extravasation of liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Successful imaging of human cancer with indium-111-labeled phospholipid vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Is half-life of circulating liposomes determined by changes in their permeability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

In-111-labeled liposomes: dosimetry and tumor depiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357002243

21 January 2018

Identifiers

DOI

10.1211/0022357002243

1 reference

6 August 2017

1 reference

PubMed ID

12542887